Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

n-GAAP earnings are projected

to rise to approximately $7.00 per diluted share by 2011.

-- Myozyme sales are expected to be approximately $275-$285 million this

year, compared to prior guidance of $320-$330 million.

-- Non-GAAP earnings per share for the second quarter are expected to be

in the mid $0.90s, reflecting ongoing investments to drive future

growth. These include investments in the U.S. launch of Renvela(R)

(sevelamer carbonate) and the expanded European introduction of

Clolar(R) (clofarabine), as well as investments in late-stage clinical

trials-particularly the phase 3 study of alemtuzumab for multiple

sclerosis. This estimate also reflects the constraints on U.S. Myozyme

sales.

First-Quarter Product Sales

-- Within the Therapeutics business, worldwide demand for Myozyme remains

robust two years into the product's launch. First-quarter sales rose

78 percent despite the delay in U.S. approval for 2000L production

capacity. Sales increased to $67.3 million from $37.9 million in the

period a year ago, driven by the number of new patients starting

therapy. As announced, the FDA will require Genzyme to submit a BLA to

obtain U.S. commercial approval for Myozyme produced at the 2000L

scale. The agency is expected to act on the application by the end of

this year.

-- First-quarter sales of Cerezyme(R) (imiglucerase for injection) rose 15

percent to $304.3 million, compared with $263.8 million in the previous

first quarter.

-- Sales of Fabrazyme(R) (agalsidase beta) grew 16 percent in the quarter,

rising to $116.5 million from $100.7 million in the first quarter last

year. Fabrazyme has captured more than a two thirds share of the

international market for Fabry disease treatment based on compelling

clinical dat
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SAN DIEGO and HONG KONG ... an innovative rare disease therapeutics enterprise, announced today that ... joined the company as vice president, research. Dr. McKew ... research, including key leadership positions at the National Institutes ... to its acquisition by Wyeth). Dr. McKew will lead aTyr,s ...
(Date:10/20/2014)... 20, 2014 Convey Computer , ... team from Iowa State University won first place in ... a Convey HC-2ex, the team’s solution achieved the highest ... than the second place finisher. , Experts from all ... the month long challenge, using a variety of design ...
(Date:10/20/2014)... , October 20, 2014 ... gastrointestinal (GI) disorders and the delivery of care has ... diseases and worrying inequalities in the provision of healthcare ... which was commissioned by United European Gastroenterology (UEG), have ... political and public awareness of the burden of GI ...
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... LEIDEN, The Netherlands, and PARSIPPANY, N.J., Feb. 10 ... CRXL ; Swiss Exchange: CRX) announced today that they ... Utrecht, The Netherlands to join their Vendor Network. Under ... pre-approved cell line generation partner for licensees of the ...
... YORK, Feb. 9 5W Public Relations, a Top 25 ... Holtorf, founder of the Holtorf Medical Group and the Yan ... Trokel to its diverse roster of clientele. Both medical centers ... relations programs."We are delighted that Dr. Kent Holtorf and the ...
... Beckman Coulter, Inc. (NYSE: BEC ) ... a quarterly dividend payout of seventeen cents ($0.17) ... March 6, 2009 to all stockholders of record ... the 79th consecutive, quarterly payout of dividends.(Logo: ...
Cached Biology Technology:DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 2DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 3DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 4DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 5The Holtorf Medical Group and Yan Center for Corrective & Cosmetic Surgery Tap 5W Public Relations 2
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... edge technologies including Wocket™, the Smart Wallet, at the ... FiRe is a leading global conference on the intersection ... by Mark Anderson , founder and publisher of ...
(Date:10/15/2014)... Johannes Gutenberg University Mainz (JGU) as a full ... to maintain a significant nationwide standing in the ... of Johannes Gutenberg University Mainz as a full ... the national and international competition for the best ... can be proud that Mainz University has been ...
(Date:10/15/2014)... awarded the 44th Rosenstiel Award for Distinguished Work in ... exploring the mechanisms of genomic instability and its implications ... the second alumnus to win the Rosenstiel Award; the ... , Alt is the Charles A. Janeway Professor of ... and an investigator at the Howard Hughes Medical Institute ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
... received an offer to establish its first foreign institute in ... proposed the sum of $86.9 million for the next 10 ... State of Florida will contribute funds to complete the financing, ... will take place. The County,s decision paved the ...
... out that older men chasing younger women contributes ... according to new findings by,researchers at Stanford and ... says that individuals should die of old age ... 55 in humans,according to demographer Cedric Puleston, a ...
... Calif., September 12, 2007 - UC Irvines Henry ... million gift from Edwards Lifesciences Corporation to establish ... next generation of cardiovascular devices. The Edwards ... interaction and collaboration among students, faculty members and ...
Cached Biology News:Palm Beach County wants to establish a Max Planck Institute in Florida 2Men shed light on the mystery of human longevity, study finds 2Men shed light on the mystery of human longevity, study finds 3Men shed light on the mystery of human longevity, study finds 4UCI receives $5M from Edwards Lifesciences 2
... The Helios gene gun system, 220-240 V, ... biomaterials into cells. This handheld device employs ... RNA-, and other biomaterial-coated gold microcarriers from ... cartridge directly into target cells. This system ...
Mouse polyclonal antibody raised against a partial recombinant MHC2TA. NCBI Entrez Gene ID = 4261...
... Digital Sight DS-L2 imaging controller is a ... DS-L1, and allows users to comfortably observe, ... DS-L2 controller features an 8.4 inch LCD ... variety of Nikon cameras including the DS-Fi1 ...
Mouse monoclonal antibody to ST8SIA2 - ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2...
Biology Products: